Alzheimer’s Disease is the most common cause of dementia. Dementia describing a specific set of symptoms such as memory loss, difficulties with problem-solving, language or simply thinking. As the disease progresses, proteins build up in the brain to form structures called ‘plaques’. Eventually there is a break between the nerve cells resulting the death of the cells and a loss of brain tissue. ending in a lack of motor skills. Although progression can vary, typically after diagnosis life expectancy is around three to nine years. Fewer than 3% of people live more than fourteen years.
Management
Medications, psychological intervention and care-giving are all available to AD patients. there are currently 5 different medications on offer for AD each have different results and side affects.
For nearly a century, medical experts have known that individuals who suffer brain trauma, such as traumatic brain injury (TBI), are at an increased risk of developing dementia later in life.
Researchers at the University of Exeter Medical School and the University of Connecticut School of Medicine found that a faulty gene linked to dementia doubles the risk of developing severe COVID-19.
Jay Sibbitts, Prof Dr Stefan H. Bossmann and Prof Dr Christopher T. Culbertson, from Kansas State University, Department of Chemistry in the U.S., underline microfluidic detection of intracellular nitric oxide levels.
Rachel Conant, Vice President Federal Affairs, Alzheimer’s Association and Alzheimer’s Impact Movement, provides us with an update on Alzheimer’s and dementia funding rises in the United States.
María J. Peláez1, Prashant Dogra1, Zhihui Wang1, Vittorio Cristini1 1Mathematics in Medicine Program, Houston Methodist Research Institute, Houston, TX 77030, USA.
Data linkage and sharing for healthy longevity together present a global challenge, in the view of Prof Makoto Suematsu, Japan Agency for Medical Research and Development and Rihana Diabo at the World Economic Forum.
If we address hearing loss, can we really decrease our risk of developing dementia? Mark Atkinson, Chief Executive Action of Hearing Loss investigates.
Prof Dr Regina Fluhrer, from the University of Augsburg, explains how intramembrane proteases have been implicated in the emergence of neurodegenerative diseases.
Diseases could be detected even before people experience symptoms, thanks to a pioneering new health-data programme as part of the government’s modern Industrial Strategy.
The University of Cambridge found that virtual reality (VR) can identify early Alzheimer’s disease better than ‘gold standard’ cognitive tests currently in use.
According to the Alzheimer Society 850,000 people in the UK have dementia but with 1 in 6 people over the age of 80 living with dementia, this is predicted to rise to over 2 million by 2050 as the population ages.
The work of the National Institute on Aging (NIA) is placed into focus here, with examples of how they are supporting vital Alzheimer’s disease research in the U.S and further afield.
Paul Edwards, Director of Clinical Services at Dementia UK, explores what dementia actually means in the 21st century, including the all-important differences between dementia and Alzheimer’s.
